Follow-up of antibody responses to human papillomavirus type 16 E7 in patients treated for cervical carcinoma

M. F. Baay, J. M. Duk, M. P. Burger, H. W. de Bruijn, E. Stolz, P. Herbrink

Research output: Contribution to journalArticleAcademicpeer-review


A synthetic peptide comprising amino acids 6-35 of HPV-16 E7 was used in an ELISA to screen sera taken from 31 cervical carcinoma patients. Sera obtained before and during treatment, and in follow-up, were tested for the presence of antibodies to this peptide. Sixteen patients with negative pretreatment serum determination remained negative during treatment and follow-up. Of the 15 patients with positive pretreatment sera, 12 showed a decrease in anti-E7 6-35 antibody level during treatment. During follow-up an increase in anti-E7/6-35 antibody level was observed in 6 out of 7 patients with progressive or recurrent disease, whereas all patients who remained in complete remission showed stable or further decreasing antibody levels. During the course of disease of the 15 seropositive patients, serum anti-E7/6-35 antibody levels were compared with serum squamous cell carcinoma antigen (SCC-Ag) profiles, a clinically useful tumor marker in the management of cervical cancer patients. Similar patterns were observed in 10 out of 15 patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Original languageEnglish
Pages (from-to)342-347
JournalJournal of Medical Virology
Issue number3
Publication statusPublished - 1995

Cite this